Covid-19 Antibody Cocktail

AstraZeneca Plc's Covid-19 antibody cocktail was found to be 77% effective in preventing symptomatic Covid-19 in high-risk people in a key trial that could expand the range of drugs available to vulnerable groups.

Outside, in letters a foot tall, the wall of the trailer reads: "GET TESTED. GET TREATED. CRUSH COVID."

AstraZeneca Plc's antibody cocktail was only 33% effective at preventing COVID-19 symptoms in people who had been exposed to the virus, failing a study that was key to the drugmaker's pandemic push.

A hospitalin Andhra Pradesh's Guntur district has administered cocktail antibodies injection 'Regeneron' to two patients. This is the first time the cocktail antibodies injection was used in Andhra Pradesh.

Zydus Cadila has sought regulatory approval for clinical trials of its antibody cocktail to treat mild COVID-19, as India grapples with a shortage of medicines and vaccines needed to effectively tackle a devastating second wave of the pandemic.

The first COVID-19 patient in India who was treated with a monoclonal antibodies cocktail was discharged from a hospital in Haryana today, a day after he was administered the jab.

"Roche India and Cipla today announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India," Cipla said in a regulatory filing to the stock exchanges

Drug major Roche India on Monday announced the launch of its first batch of antibody cocktail against COVID-19 in India. The antibody cocktail -- Casirivimab and Imdevimab -- is priced at Rs 59,750 per dose. Roche's antibody cocktail was given to for

British drugmaker AstraZeneca has begun testing an antibody-based cocktail for the prevention and treatment of COVID-19, adding to recent signs of progress on possible medical solutions to the disease caused by the novel coronavirus.

AstraZeneca Plc's Covid-19 antibody cocktail was found to be 77% effective in preventing symptomatic Covid-19 in high-risk people in a key trial that could expand the range of drugs available to vulnerable groups.

Outside, in letters a foot tall, the wall of the trailer reads: "GET TESTED. GET TREATED. CRUSH COVID."

AstraZeneca Plc's antibody cocktail was only 33% effective at preventing COVID-19 symptoms in people who had been exposed to the virus, failing a study that was key to the drugmaker's pandemic push.

A hospitalin Andhra Pradesh's Guntur district has administered cocktail antibodies injection 'Regeneron' to two patients. This is the first time the cocktail antibodies injection was used in Andhra Pradesh.

Zydus Cadila has sought regulatory approval for clinical trials of its antibody cocktail to treat mild COVID-19, as India grapples with a shortage of medicines and vaccines needed to effectively tackle a devastating second wave of the pandemic.

The first COVID-19 patient in India who was treated with a monoclonal antibodies cocktail was discharged from a hospital in Haryana today, a day after he was administered the jab.

"Roche India and Cipla today announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India," Cipla said in a regulatory filing to the stock exchanges

Drug major Roche India on Monday announced the launch of its first batch of antibody cocktail against COVID-19 in India. The antibody cocktail -- Casirivimab and Imdevimab -- is priced at Rs 59,750 per dose. Roche's antibody cocktail was given to for

British drugmaker AstraZeneca has begun testing an antibody-based cocktail for the prevention and treatment of COVID-19, adding to recent signs of progress on possible medical solutions to the disease caused by the novel coronavirus.